Reblozyl (luspatercept) Preparation & Administration | B-Thalassemia
Reblozyl reconstitution and preparation instructions for subcutaneous administration in Beta-Thalassemia patients
Search results
B-Thalassemia Dosing Modification | Reblozyl (luspatercept)
Reblozyl dosage for β-Thalassemia patients – guidelines for tailoring the dosage based on patient response to Reblozyl
Starting with Reblozyl in B-Thalassemia | Reblozyl (luspatercept)
β-Thalassemia prescribing data for Reblozyl, including starting doses and monitoring requirements to maximise efficacy and safety
Discontinuations in B-Thalassemia | Reblozyl (luspatercept)
Reblozyl adverse drug reactions – safety and discontinuation rates for Reblozyl in Beta-Thalassemia patients with Red Blood Cell Transfusion dependent anemia
Adverse Reactions in B-Thalassemia | Reblozyl (luspatercept)
Reblozyl selected adverse drug reactions – safety data for treatment of β-Thalassemia patients with Red Blood Cell transfusion dependent anemia
Reblozyl (luspatercept) Safety Profile for B-Thalassemia
Detailed Reblozyl safety information for treatment of Beta-Thalassemia patients. List of adverse drug reactions and discontinuation rates. Find out more
Reduce Serum Ferritin Levels in B-Thalassemia | Reblozyl (luspatercept)
RBC T dependent B-Thalassemia patients often need iron chelation therapy. By reducing transfusion burden, Reblozyl reduces iron overload (serum ferritin)
Reduce Transfusion Burden in B-Thalassemia | Reblozyl (luspatercept)
Reblozyl improves erythroid maturation in β-Thalassemia patients, helping reduce Red Blood Cell transfusions by at least 33%. Read more
Special Warnings and Precautions in B-Thalassemia | Reblozyl (luspatercept)
Reblozyl special warnings and precautions for prescribing Reblozyl to B-Thalassemia patients
Contraindications in B-Thalassemia | Reblozyl (luspatercept)
Contraindications for Reblozyl in B-Thalassemia patients – Overview of contraindications, which include pregnancy and hypersensitivity to ingredients
B-Thalassemia Patient Eligibility for Reblozyl (luspatercept)
Review patient eligibility criteria, contraindications and special precautions for prescribing Reblozyl (luspatercept) for β-Thalassemia patients. Read the guide
Reblozyl (luspatercept) Mechanisms – B-Thalassemia
Reblozyl is the first and only erythroid maturation agent. Learn more on erythropoiesis and B-Thalassemia
Limitations of Therapy in B-Thalassemia | Reblozyl (luspatercept)
Limitations of current B-Thalassemia therapies – risks and implications of regular Red Blood Cell transfusions and iron chelation for B-Thalassemia patients
Classifying B-Thalassemia | Reblozyl (luspatercept)
Classification of B-Thalassemia types – Overview of features of minor (trait), intermedia and major and their dependence on Red Blood Cell transfusion
Prevalence of B-Thalassemia | Reblozyl (luspatercept)
B-Thalassemia epidemiology – key facts and information regarding the global incidence of Beta-Thalassemia
Characteristics of B-Thalassemia | Reblozyl (luspatercept)
Understanding Beta-Thalassemia – characteristics of the disease and how to support patients with Red Blood Cell transfusion dependent anemia
Beta-Thalassemia Condition, Symptoms and Treatment
Beta-Thalassemia information resource to help health care practitioners supporting patients with red blood cell transfusion dependent anemia. Read more
Preparation & Administration in MDS | Reblozyl (luspatercept)
Reblozyl preparation instructions for subcutaneous administration to MDS patients with RBC dependent anemia. Read more
Dosing Modification in MDS | Reblozyl (luspatercept)
Reblozyl dosage guidelines for MDS patients – information for tailoring the dosage based on patient response to Reblozyl
Starting with Reblozyl in MDS | Reblozyl (luspatercept)
Starting doses and monitoring requirements to maximise efficacy and safety of Reblozyl in MDS patients. Read more
Discontinuations in MDS | Reblozyl (luspatercept)
Reblozyl safety and discontinuation rates for MDS patients with red blood cell transfusion dependent anemia. Read more
Selected Adverse Reactions in MDS | Reblozyl (luspatercept)
Reblozyl clinical safety data for the treatment of MDS patients with RBC transfusion dependent anemia. Read more
Reblozyl (luspatercept) MDS Patient Safety Information
Detailed Reblozyl safety information for treatment of MDS patients. Full disclosure of drug reactions and discontinuation rates. Find out more
Various MDS Patient Groups Benefit | Reblozyl (luspatercept)
Reblozyl significantly reduces the RBC transfusion burden in multiple subgroups of MDS patients
Reduce Serum Ferritin Levels in MDS | Reblozyl (luspatercept)
By reducing transfusion burden Reblozyl reduces iron overload (serum ferritin)
Rapid and Sustained Response in MDS | Reblozyl (luspatercept)
62.1% of Reblozyl responders had 2 or more episodes of red blood cell transfusion independence, with rapid increases in hemoglobin levels
Improve Hemoglobin Levels in MDS | Reblozyl (luspatercept)
Reblozyl is an erythroid maturation agent delivers a significant hematologic improvement using clinically relevant IWG criteria in MDS patients
Reduce or Eliminate Transfusions in MDS | Reblozyl (luspatercept)
Reblozyl is an erythroid maturation agent that helps MDS patients with RBC transfusion dependent anemia to decrease or even eliminate transfusion burden. Read more
Special Warnings and Precautions in MDS | Reblozyl (luspatercept)
Reblozyl special warnings and precautions – side effects and precautions for prescribing Reblozyl to MDS patients
Contraindications in MDS | Reblozyl (luspatercept)
Contraindications for Reblozyl in B-Thalassemia patients, including pregnancy and hypersensitivity to ingredients
Myelodysplastic Syndromes (MDS) | Reblozyl (luspatercept)
Reblozyl (luspatercept) – Erythroid maturation agent for patients with MDS-associated anemia who are Red Blood Cell Transfusion dependent
Reblozyl (luspatercept) Erythroid Maturation Agent
Reblozyl (luspatercept) erythroid maturation agent for transfusion dependent anemia patients with MDS (very low to intermediate risk) or Beta-Thalassemia
ESA Response Status in MDS | Reblozyl (luspatercept)
Reblozyl is indicated for patients with an unsatisfactory response or those ineligible for erythropoiesis-stimulating agents (ESAs) . Read more
RS Status in MDS | Reblozyl (luspatercept)
Outline of Reblozyl eligibility criteria for ring sideroblast (RS) levels in bone marrow aspirate with or without SF3B1 mutation
Why IPSS-R | Reblozyl (luspatercept)
Use the International Prognosis Scoring System-Revised (IPSS-R) to identify very low-risk, low-risk and intermediate-risk patients who may be eligible for Reblozyl
Mechanism of Action in MDS | Reblozyl (luspatercept)
Reblozyl is the first and only Erythroid Maturation Agent. Find out more on how ineffective erytheopoiesis causes anemia in MDS